This is a Briumvi news story, published by Investor's Business Daily, that relates primarily to TG Therapeutics news.
For more Briumvi news, you can click here:
more Briumvi newsFor more stocks trading & speculation news, you can click here:
more stocks trading & speculation newsFor more news from Investor's Business Daily, you can click here:
more news from Investor's Business DailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best business news, entertainment news, world news, and much more. If you like stocks trading & speculation news, you might also like this article about
TG Therapeutics stock. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest TGTX news, Briumvi sales news, stocks trading & speculation news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
TG TherapeuticsInvestor's Business Daily
•
83% Informative
TG Therapeutics (TGTX) stock crashed Monday after missing third-quarter profit expectations.
Sales of Briumvi , the MS drug, topped expectations at $83.3 million .
Analysts projected $77.4 million .
For the year , the company now expects $300 million to $305 million in sales of the drug.
VR Score
88
Informative language
92
Neutral language
15
Article tone
formal
Language
English
Language complexity
39
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
3
Source diversity
3
Affiliate links
no affiliate links